Glaucoma not just affects elderly though but keeps being the majority.
My question for both sides of the table here in HC, is what would it take to re-rate this company to a P/S of 4.0 for instance? We usually have an answer from 007, but would like to hear from others _less positive_ than 007 with their reasoning.
Yes, we know that the revenue is decreasing in the short term, but it is basically staying at the same P/S that it was a year ago... with a better product than two years ago (nobody can take that away from EYE) growth potential in Asia (which other companies don't seem to have) and a possible big partnership in the cards, without counting other confidential developments they might have.
Why is it at a P/S of 1.5 still? why? why?
I'm way too exposed to EYE now, and painfully in the red, but I still believe in the company.
GLTAH
EYE Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)